£790.00

The 2025-2030 World Outlook for Beta Interferon Therapeutics for Multiple Sclerosis

Subjects

Price data last checked 20 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£790 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 71 days · 71 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 71 days • 1 price levels

Days at Price

Price Analysis

Most common price: £790 (71 days, 100.0%)

Price range: £790 - £790

Price levels: 1 different prices over 71 days

Description

This study covers the world outlook for beta interferon therapeutics for multiple sclerosis across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of beta interferon therapeutics for multiple sclerosis as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Bayer, Biogen, Merck & Company, Novartis International, Pfizer, Sanofi, and Teva Pharmaceutical Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).

Product Specifications

Format: paperback
ASIN: B0CZM1MDKJ
Category: Books > Subjects
Domain: Amazon UK
Release Date: 03 March 2024
Listed Since: 07 May 2024

The 2025-2030 World Outlook for Beta Interferon Therapeutics for Multiple Sclerosis

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Beta Interferon Therapeutics for Multiple Sclerosis in India

The 2023-2028 Outlook for Beta Interferon Therapeutics for Multiple Sclerosis in the United States

The 2023-2028 Outlook for Beta Interferon Therapeutics for Multiple Sclerosis in Japan

The 2023-2028 Outlook for Beta Interferon Therapeutics for Multiple Sclerosis for US Zip Codes

The 2016-2021 Outlook for Multiple Sclerosis Therapeutics in the United States

The 2016 Report on Multiple Sclerosis Therapeutics: World Market Segmentation by City

The 2023 Report on Multiple Sclerosis Therapeutics: World Market Segmentation by City

The 2023 Report on Multiple Sclerosis Treatments: World Market Segmentation by City

The 2023-2028 Outlook for Advanced Therapy Medicinal Products in India

The 2023-2028 Outlook for Advanced Therapy Medicinal Products in the United States

The 2023-2028 World Outlook for Advanced Therapy Medicinal Products

The 2023-2028 Outlook for Anti-Inflammatory Scleroderma Drugs in the United States

Multiple Sclerosis - Pathways, Diagnosis and Therapeutic Targets (Nervous System and Mental Health)

The 2023-2028 Outlook for Anti-Inflammatory Scleroderma Drugs in India

Living with Multiple Sclerosis: A Group-Based Psychological Support Intervention for Newly Diagnosed People with MS (LiMS)

The 2026-2031 World Outlook for Digital Therapeutics Sales

The 2023-2028 Outlook for Medical Foods in the United States

The 2025-2030 World Outlook for Digital Therapeutics Sales

The 2025-2030 World Outlook for T-Cell Immunotherapies

Multiple Sclerosis in Children and Adolescents - Medical Book

Multiple Sclerosis - Genetics, Disease Mechanisms and Clinical Developments

The 2026-2031 World Outlook for Micro-Magnetic Resonance Imaging for Small Animal Imaging (In-Vivo)

The 2016-2021 Outlook for Therapeutic Monoclonal Antibody (Mab)-Based Products in India

The 2026-2031 World Outlook for Anti-Inflammatory Scleroderma Drugs